Phase 2 Esophageal Squamous Cell Carcinoma Clinical Trials
71 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 71 trials
Recruiting
Phase 1Phase 2
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
Oesophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC60 enrolled7 locationsNCT07405151
Recruiting
Phase 2
Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma (ESCC)
Second Affiliated Hospital of Zunyi Medical University92 enrolled1 locationNCT07559045
Recruiting
Phase 2
Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma
Esophageal Squamous Cell Carcinoma (ESCC)
University Hospital, Clermont-Ferrand95 enrolled30 locationsNCT07205731
Recruiting
Phase 2
A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma
Advanced Esophageal Squamous Cell Carcinoma
Shanghai Junshi Bioscience Co., Ltd.280 enrolled1 locationNCT07484724
Recruiting
Phase 1Phase 2
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Squamous Cell CarcinomaAdvanced or Metastatic Squamous Non-Small Cell Lung CancerAdvanced Head and Neck Squamous Cell Carcinoma+4 more
Hummingbird Bioscience398 enrolled20 locationsNCT05910827
Recruiting
Phase 2
Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
Nanfang Hospital, Southern Medical University30 enrolled1 locationNCT06885814
Recruiting
Phase 2
Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC
Esophageal Squamous Cell CarcinomaLocally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Sichuan University118 enrolled1 locationNCT07519486
Recruiting
Phase 2
Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC
Esophageal Squamous Cell Carcinoma
Fudan University104 enrolled1 locationNCT07403136
Recruiting
Phase 2
Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Ning Jiang, M.D./Ph.D.98 enrolled1 locationNCT07530094
Recruiting
Phase 1Phase 2
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC298 enrolled42 locationsNCT06780111
Recruiting
Phase 2
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)+2 more
AstraZeneca257 enrolled59 locationsNCT06535607
Recruiting
Phase 1Phase 2
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Breast CancerOvarian CancerCervical Cancer+5 more
Terremoto Biosciences Inc.205 enrolled15 locationsNCT07109726
Recruiting
Phase 2
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
Esophageal Squamous Cell Carcinoma (ESCC)
Beijing Konruns Pharmaceutical Co., Ltd.60 enrolled1 locationNCT07481058
Recruiting
Phase 1Phase 2
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC230 enrolled57 locationsNCT05319730
Recruiting
Phase 2
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
Resectable Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital46 enrolled1 locationNCT07457528
Recruiting
Phase 1Phase 2
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Esophageal Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaSquamous Non-small-cell Lung Cancer+1 more
Alentis Therapeutics AG170 enrolled38 locationsNCT06747585
Recruiting
Phase 2
Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Jiangsu Cancer Institute & Hospital22 enrolled1 locationNCT07435454
Recruiting
Phase 2
Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study
Esophageal Squamous Cell Carcinoma
The Affiliated Hospital of Putian University42 enrolled1 locationNCT07437898
Recruiting
Phase 2
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma (ESCC)Locally Advanced Unresectable Esophageal Cancer
Ming-Yu Lien45 enrolled8 locationsNCT07039162
Recruiting
Phase 1Phase 2
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
Esophageal Squamous Cell CarcinomaNeoadjuvantIvonescimab
Tang-Du Hospital45 enrolled1 locationNCT07385001